- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03328676
The Effect of Cannabis on Dementia Related Agitation and Aggression
A Phase II, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Avidekel Oil for the Treatment of Subjects With Agitation Related to Dementia
The most common syndrome in patients with severe dementia is agitated behavior, which is often characterized by a combination of violent behavior (physical or verbal), restlessness, and inappropriate loudness. The treatment options for this syndrome are limited and lead to severe side effects. In vivo experiments on animals and clinical studies on adults show that cannabinoids could have a beneficial effect on behavioral disorders in general, and in dementia-related disorders in particular.
Additionally, medical cannabis patients have reported that cannabis aids in pain relief, increased appetite, and a sense of calm and peace of mind. Elderly patients suffering from dementia that experience this syndrome could also benefit from other quality of life aspects of the cannabis treatment such as reduction in medication consumption, weight gain and improvement of sleep.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this randomized, double-blind placebo-controlled trial, 60 patients will be randomly assigned to receive either CBD-A (30:1) cannabis rich low THC oil (30% CBD and 1% THC) or a placebo oil. The primary efficacy endpoint was a decrease of four or more points on the Cohen-Mansfield Agitation Inventory (CMAI) score by week 16, as compared to baseline. Secondary endpoints included improvement of other neurobehavioral symptoms.
The following questionnaires will be administered by trained staff at every visit: The CMAI, a to measure the types and frequencies of agitated behaviors, and the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) to measure behavioral disturbances.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Netanya, Israel
- Laniado Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects > 60 years old.
- Written informed consent from participants legally authorized representative.
- Subjects who are residing either in an institutionalized setting (e.g. dementia unit, nursing home, assisted living facility, or other residential care facility) or in a non-institutionalized setting where the subject is not living alone and is receiving 24-hour supervision via home health care or a family member. Subjects must have been at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the trial.
- Diagnosis of Dementia (NCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) Criteria for at least 6 months prior to screening.
- Mini-Mental State Examination (MMSE) < 26.
- Clinically relevant Behavioral and Psychological Symptoms of Dementia (BPSD) operationally defined as NPI-NH agitation/ aggression sub score of ≥3 at screening.
- Documented history of clinically relevant BPSD.
- Ability to participate in study evaluation and ingest oral medication.
- Subjects will be on stable concomitant medications regimen for the treatment of BPSD for at least one month prior to the screening visit.
- Subjects will be on stable concomitant medications regimen for the treatment of concurrent conditions for at least one month prior to the screening visit.
Exclusion Criteria:
- Patients receiving any of the following medications: Astemizole, Cisapride, Pimozide or Terfenadine.
- The agitation/aggression is attributable to concomitant medications, environmental conditions or psychiatric condition.
- Patients with severe heart disease.
- Subjects suffering from Epilepsy.
- Subjects suffering from anxiety disorder.
- Subjects who had psychiatric condition in the past OR suffering from psychosis.
- Schizophrenia OR family history of Schizophrenia OR any other mental disorder.
- Subjects with any other condition, which in the judgment of the investigator would prevent the subject from completing the study.
- Any condition that the Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient.
- Patients suffering from alcohol and/or substance abuse
- Surgery within 30 days prior to screening or scheduled surgery during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: "Avidekel " cannabis oil 20:1 CBD:THC
The cannabis oil will be mad out of extract from the Avidekel strain and olive oil.
Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC.
Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
|
Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Other Names:
|
Placebo Comparator: placebo oil
Patients in the control group will receive placebo.
|
Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in score of Cohen-Mansfield Agitation Inventory (CMAI)
Time Frame: week 16
|
Proportion of subjects achieving a decrease of four or more points on the Cohen-Mansfield Agitation Inventory (CMAI), a 29-item scale that measures the types and frequencies of agitated behaviors, each rated on a 7-point scale of frequency, where higher scores indicate greater agitation severity.
|
week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in score of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH)
Time Frame: week 16
|
Proportion of subjects with change in score of Neuropsychiatric Inventory-Nursing Home Version (NPI-NH).
The greater the NPI-NH score, the more severe and frequent the behavioral disturbances
|
week 16
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vered Hermush, Dr, Laniado Hospital Geriatric Department
Publications and helpful links
General Publications
- Solomon HV, Greenstein AP, DeLisi LE. Cannabis Use in Older Adults: A Perspective. Harv Rev Psychiatry. 2021 May-Jun 01;29(3):225-233. doi: 10.1097/HRP.0000000000000289.
- Hermush V, Ore L, Stern N, Mizrahi N, Fried M, Krivoshey M, Staghon E, Lederman VE, Bar-Lev Schleider L. Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. Front Med (Lausanne). 2022 Sep 6;9:951889. doi: 10.3389/fmed.2022.951889. eCollection 2022.
- Bosnjak Kuharic D, Markovic D, Brkovic T, Jeric Kegalj M, Rubic Z, Vuica Vukasovic A, Jeroncic A, Puljak L. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2021 Sep 17;9(9):CD012820. doi: 10.1002/14651858.CD012820.pub2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Dyskinesias
- Psychomotor Disorders
- Psychomotor Agitation
- Dementia
- Physiological Effects of Drugs
- Protective Agents
- Antimutagenic Agents
- Chlorophyllin
Other Study ID Numbers
- TO_D02_2016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Agitation Related to Dementia
-
IGC Pharma LLCRecruitingAggression | Depression | Anxiety | Alzheimer Disease | Memory Impairment | Agitated; State, Acute Reaction to Stress | Agitation,Psychomotor | Care Giving Burden | NPS | Aggressive OutburstUnited States, Canada, Puerto Rico
-
State University of New York - Upstate Medical...CompletedAgitated; State, Acute Reaction to Stress | Agitation,PsychomotorUnited States
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedAlzheimer Dementia | Agitation Associated With Alzheimer's DementiaUnited States
-
Axsome Therapeutics, Inc.CompletedAlzheimer Disease | Agitation in Patients With Dementia of the Alzheimer's Type | Agitation,PsychomotorUnited States, Canada
-
Brent ForesterMedical University of South Carolina; Mayo Clinic; Emory University; The Zucker... and other collaboratorsRecruitingAlzheimer Dementia | Agitation,PsychomotorUnited States
-
Axsome Therapeutics, Inc.CompletedAlzheimer Disease | Agitation in Patients With Dementia of the Alzheimer's Type | Agitation,PsychomotorUnited States, Australia
-
Ralph H. Johnson VA Medical CenterJHSPH Center for Clinical TrialsNot yet recruitingBehavioral Symptoms | Agitation,Psychomotor | Dementia Moderate | Dementia SevereUnited States
-
Axsome Therapeutics, Inc.Enrolling by invitationAlzheimer Disease | Agitation in Patients With Dementia of the Alzheimer's Type | Agitation, PsychomotorUnited States, Canada
-
Sykehuset Innlandet HFCompletedAgitation Aggression in DementiaNorway
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAgitation in Patients With Dementia of the Alzheimer's TypeUnited States, Spain, Hungary, Italy, Canada, Czechia, South Africa, Poland, Bulgaria, France
Clinical Trials on Cannabis
-
University of California, San DiegoRecruiting
-
Germans Trias i Pujol HospitalIstituto Superiore di Sanità; Fundació Institut Germans Trias i PujolCompletedHealthy Subjects | Cannabis UseSpain
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
Khon Kaen UniversityEnrolling by invitationSpinal Cord InjuryThailand
-
Centre hospitalier de l'Université de Montréal...Completed
-
Bayliss J. Camp, PhDRecruitingDriving Impaired | Cannabis SmokingUnited States
-
Rambam Health Care CampusCompleted1- Cancer Patients During Chemotherapy Treatment | 2- Use of Cannabis Comparing to Control Without Cannabis UseIsrael
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Use | Cannabis | Cardiovascular Risk Factor | Nicotine Dependence | Cigarette Smoking | THC | Nicotine Withdrawal | Cannabis Smoking | Cannabis Use, UnspecifiedUnited States
-
New York State Psychiatric InstituteSuspended
-
Center for Medicinal Cannabis ResearchCompleted